BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

To Leerink Partners analyst Daina Graybosch, BioNTech’s acquisition of CureVac is essentially a hedge against legal and financial uncertainty. The …